Canada’s Applied Research in Cancer Control Conference
145 Richmond Street West
The Canadian Centre for Applied Research in Cancer Control (ARCC) is pleased to announce that its 5th annual conference will take place from May 8th to 9th at the Hilton Toronto in Toronto, Ontario. The objective of this conference is to bridge a connection between researchers and decision-makers, using health economics, services, policy and ethics research to improve cancer control and the delivery of cancer care.
Dr. Melissa Brouwers, MA, PhD (Special Session)
Melissa Brouwers is an Associate Professor and Health Services Research Lead in the Department of Oncology, McMaster University; Provincial Director of the Program in Evidence-based Care, Cancer Care Ontario; National Lead for the Capacity Enhancement Project of the Canadian Partnership Against Cancer; and KT Lead for The Canadian Centre for Applied Research in Cancer Control (ARCC).
Dr. Brouwers holds a BSc in Psychology from the University of Toronto and an MA and PhD in Psychology from the University of Western Ontario. She is an active and leading member of various national and international research groups including a member of the Clinical Guidelines (CG) Action Group of the Canadian Partnership Against Cancer, and the Lead of the AGREE Research Enterprise (Principal Investigator of AGREE Next Steps Project, upcoming AGREE A3 Project and the AGREE Research Trust).
Prof. Jonathan Emery, MB BCh DPhil, DRCOG, RCGP (Plenary Panelist)
Prof Jon Emery is the Herman Professor of Primary Care Cancer Research at the University of Melbourne, a new Chair developed within the Victorian Comprehensive Cancer Centre. He is an NHMRC Practitioner Fellow, Director of the Cancer Australia Primary Care Collaborative Cancer Clinical Trials Group (PC4), and a Visiting Research Fellow at the University of Cambridge.
He studied medicine at Cambridge and Oxford and obtained his DPhil at Oxford on computer decision support to assess cancer risk in general practice. His research focuses on the role of primary care across the cancer continuum, and primary care trials of complex interventions. He leads a parallel program of cancer research between Melbourne and Cambridge on cancer screening, risk assessment and early diagnosis. He has published over 170 papers and has been a Chief Investigator on research grants and awards totalling over $AUD16 million and GBP11 million. He sits on several national advisory committees related to cancer screening and diagnosis, and cancer research.
Dr. Doris Howell, RN, PhD (Plenary Panelist)
Dr. Doris Howell was trained as a health services researcher and is also focused on clinical intervention research. The goal of Dr. Howell’s research program is to improve the patient’s experience of cancer care, through health intervention research focused on better care delivery systems and clinical interventions for complex symptoms (fatigue, breathlessness, pain). Her main focus of intervention research is on understanding how psychological factors such as beliefs influence symptom response and adaptation to illness and how these might be modified through behavioral self-management interventions. Additionally, the efficacy and effectiveness of nurse-led behavioral self-management interventions in reducing symptom distress is a clinical research focus.
Dr. Howell leads standards and guideline development and is a member of the national distress management implementation team under the Canadian Partnership Against Cancer. Dr. Howell has a leadership role in Cancer Care Ontario in Patient-Reported Outcomes.
Dr. Jon Kerner, PhD (Special Session)
Dr. Jon Kerner joined the Partnership in 2008 and currently serves as Expert Lead, Knowledge Mobilization and Evaluation. He also serves as Chair of the Knowledge Mobilization Steering Committee. Dr. Kerner’s past roles with the Partnership include Senior Scientific Leader, Population Health and Knowledge Management; Senior Scientific Advisor, Knowledge Translation; and Chair of the Primary Prevention Advisory and Action Groups.
Dr. Kerner obtained a Bachelor of Science from McGill University and his PhD in community psychology from New York University. He received post-doctoral training in cancer epidemiology, biostatistics and clinical trials design from the Johns Hopkins University School of Public Health.
Prior to joining the Partnership, Dr. Kerner served as the Deputy Director for Research Dissemination and Diffusion of the Division of Cancer Control and Population Sciences at the U.S. National Cancer Institute. Before that he spent 20 years as a peer-reviewed and funded researcher at two National Cancer Institute-designated comprehensive cancer centres: Memorial Sloan Kettering Cancer Center and Georgetown University’s Lombardi Cancer Center. His community-based cancer control research integrated behavioural science, cancer epidemiology, and health services research and the development of research, practice, and policy partnerships within low income and medically underserved communities. He served on numerous national grant review panels and was the first chair of the National Institutes of Health’s (NIH) Community Prevention and Control Study Section (now the Community-Led Health Promotion Study Section).
Dr. Eshwar Kumar, MD (Plenary Panelist)
Dr. Eshwar Kumar has been Co-CEO of the New Brunswick Cancer Network, a division of the New Brunswick Department of Health since 2005.
He was Head of the Department of Oncology and Medical Director of the Oncology Program at the Atlantic Health Sciences Corporation, Saint John, NB, from June 1994 – March 2009. He is an Assistant Professor in the Department of Radiation Oncology at Dalhousie University, Halifax.
A graduate of St Johns Medical College at Bangalore University, India, he obtained his Fellowship in Radiotherapy and Oncology from the Royal College of Radiologists, London, UK in 1982. He has been practicing as a Radiation Oncologist in Saint John, New Brunswick since 1984 with a special interest in the management of breast cancer, lymphomas, GU cancer and thyroid cancer.
He is currently on the Board of Directors of the Canadian Association of Provincial Cancer Agencies (CAPCA) as well as the Board of Directors of Canadian Partnership Against Cancer (CPAC). He also serves as a surveyor for Accreditation Canada.
He has been an active volunteer with the Canadian Cancer Society for over sixteen years and was the President of the New Brunswick division from 2007 – 2009. He has been on the National Board of the Canadian Cancer Society for the last six years.
Dr. Robin McLeod, MD, FRCS(C) (Special Session)
As Vice-President, Clinical Programs and Quality Initiatives, Dr. Robin McLeod works with clinical leaders across the province to improve the quality and coordination of cancer care. Previously, she served for 7 years as Surgical Lead, Quality and Knowledge Transfer. In that role, Robin led or co-led a number of initiatives including the regionalization of hepatobiliary pancreas and thoracic surgery in Ontario, the development of evidence-based guidelines in cancer surgery, the development of a gynecological oncology organizational guideline, and the development of quality-based procedure funding for cancer surgery.
Robin received a BSc and MD from the University of Alberta. Following this, she completed training in general surgery at the University of Toronto, colorectal surgery at the Cleveland Clinic, and did training in clinical epidemiology at McMaster University before joining the faculty at the University of Toronto in 1985.
Dr. Michael Sherar, PhD (Plenary Keynote)
Dr. Michael Sherar is President and CEO of Cancer Care Ontario. a role he was appointed in 2011. From 2006 to 2011, he was the provincial agency’s Vice-President, Planning and Regional Programs, leading the development of Regional Cancer Programs, Including capital planning for cancer services across the province.
Dr. Sherar is an Affiliate Scientist at the Techna Institute University Health Network where he carries out research and development of minimally invasive thermal therapy technologies for cancer including radiofrequency ablation.
Dr. Sherar received a BA in Physics from Oxford University in 1985 and his PhD in Medical Biophysics from University of Toronto in 1989.
The Canadian Centre for Applied Research in Cancer Control (ARCC) is no longer accepting abstract submissions to be presented at our fifth annual conference being held May 8th -9th in Toronto, Ontario. The ARCC Conference is Canada’s only applied cancer control research conference, bringing together policy & decision makers, researchers, clinicians, trainees, and other stakeholders to share work in the areas of health economics, services, policy, and ethics as it relates to cancer control in Canada. We thank everyone who applied and hope to see everyone at the conference this year.
The 2016 ARCC Conference will be hosted at the Hilton Hotel in Toronto, Ontario.
Early Bird Registration Rates:
Student member $50
Student non-member 100
Emerging Leaders $50
“Early Bird Registration Rates are in effect from January 8th, 2016 – April 15th, 2016”
**If you are a new professional (within 5 years of receiving your terminal degree) please email ARCC@cancercare.on.ca for a registration code and receive student rates!!!
**NEW** When you register for the ARCC Conference you will receive a promotional code that will save you 10% off registration for CAHSPR
ARCC will again be offering travel support for students presenting at our conference. To be eligible for a student travel award, the student must be submitting an abstract to and presenting at the 2016 ARCC conference. The application for student travel awards is electronic and will only be available in parallel with abstract submission. If you have any questions, please contact ARCC@cancercare.on.ca
Dr. Claire de Oliveira, MA, PhD (Conference Co-Chair)
Claire de Oliveira is an Independent Scientist and Health Economist at the Centre for Addiction and Mental Health (CAMH) and an Assistant Professor at the Institute of Health Policy, Management and Evaluation (IHPME) at the University of Toronto. She is also a collaborator at the Toronto Health Economics Technology Assessment Collaborative (THETA). Her main areas of cancer-related research include the development of costing methodology and the use of administrative health care data to measure health services utilization and costs. She also has extensive experience with regression modeling. Her active projects includes a large-scale CIHR-funded study that seeks to estimate the costs of cancer care for adults in British Columbia, Manitoba, Ontario, Quebec and Nova Scotia using linked administrative health care data. She is also involved in a similar study that involves the estimation of costs of pediatric cancer care in British Columbia and Ontario.
Dr. Eva Grunfeld, MSc, MD, FCFP, DPhil (Conference Co-Chair)
Dr. Eva Grunfeld is a leader in cancer health services and outcomes research. Her research focuses on evaluation and knowledge translation of cancer health services, covering the entire spectrum of cancer control activities. She is internationally recognized for making important contributions to the literature on cancer follow-up, and cancer survivorship. She is a physician scientist with the Ontario Institute of Cancer Research, Health Services Research Program and Director of the Knowledge Translation Research Network. At the same time she is the Giblon Professor and Director of Family Medicine Research at the Department of Family and Community Medicine, University of Toronto. From 2004 to 2008 she founded and directed the Cancer Outcomes Research Program at Cancer Care Nova Scotia and Dalhousie University.
Dr. Kelvin Chan, MD, FRCP, MSc - (ARCC Co-Director)
Dr. Kelvin Chan is a medical oncologist at Sunnybrook Odette Cancer Centre and an Assistant Professor at the University of Toronto. He is also a clinical epidemiologist with a focus in health economics, and a biostatistician. His research interests include health services research, health technology and drug assessments, economic evaluations, systematic review and meta-analysis including network meta-analysis. Professionally, he is interested in drug funding and reimbursement issues. He is a member of Ontario’s Committee to Evaluate Drugs (CED) and the Ontario Steering Committee of Cancer Drugs (OSCCD). He is also the clinical lead of the Provincial Drug Reimbursement Programs (RPDP) at Cancer Care Ontario (CCO).
Dr. Stuart Peacock, PhD - (ARCC Co-Director)
Stuart Peacock holds the Leslie Diamond Chair in Cancer Survivorship and is a Professor in the Faculty of Health Sciences, Simon Fraser University. He is currently Co-Director of the Canadian Centre for Applied Research in Cancer Control (ARCC). ARCC is a pan-Canadian research centre providing interdisciplinary leadership in health economics, services, policy and ethics research. Stuart is also a Distinguished Scientist in Cancer Control Research at the BC Cancer Agency, a member of the Board of Directors of the Canadian Agency for Drugs and Technologies in Health, and past President of the International Society on Priorities in Health Care. He has held university positions in Canada, Australia and the UK. Over the past 20 years, Stuart’s main research interests have focused on research into developing more effective cancer services, making health system funding decisions fairer and more transparent, and improving the quality of life of cancer patients and survivors.